Testosterone Levels by Age Chart: What's Normal, What's Low, and When to Act (2026)

Executive Summary

The most common mistake men make when reading a testosterone result is treating the number in isolation — comparing it against the lab's reference range and concluding they are 'fine' or 'low' without additional context. A testosterone level of 320 ng/dL in a 35-year-old with symptoms of hypogonadism is clinically different from the same number in an 80-year-old without symptoms. The number matters. The context matters more.

Testosterone levels decline with age — this is well-established. But the decline is not linear, it is not universal, and it does not automatically require treatment. At the same time, many men with testosterone levels in the lower third of the 'normal range' (roughly 300–500 ng/dL) experience significant symptoms that respond well to evaluation and often to treatment — while other men at similar levels feel completely fine. Symptoms plus lab confirmation plus free testosterone context is the diagnostic standard, not a single total T number.

This guide gives you the decade-by-decade reference data you are looking for, explains why the standard 'normal range' used by most labs is clinically misleading, covers the critical role of SHBG and free testosterone in accurate interpretation, and provides a practical framework for deciding when a testosterone level actually warrants attention. For the full symptom picture, see low testosterone symptoms. For the complete lab interpretation guide, see how to read testosterone lab results.

At-a-Glance Comparison

Reference data based on population studies including the Hypogonadism in Males (HIM) study, NHANES III, and Bhasin 2019 AUA guidelines. Individual variation is substantial — ranges represent approximate 5th–95th percentile population data, not health thresholds. Morning draw (7–10 AM) required for valid comparison. Updated 2026.

Why the lab's 'normal range' is clinically misleading — and what to use instead

When most men get a testosterone lab result, they see a range printed on the report — something like 264–916 ng/dL (the LabCorp standard range). This range is a statistical population reference range, derived from measurements across all adult men ages 18–99. It is not a health threshold, not a symptom-correlation threshold, and not an age-adjusted target. It means that 95% of adult men across all ages tested above 264 ng/dL. A 28-year-old at 270 ng/dL and a 79-year-old at 270 ng/dL both fall within the 'normal range' — but their clinical pictures are completely different. Buyers searching for testosterone levels by age chart usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The American Urological Association (AUA) addressed this directly in their 2018 and 2022 guidelines: the diagnosis of clinical hypogonadism requires both a low testosterone level AND symptoms consistent with testosterone deficiency. The AUA uses 300 ng/dL as the biochemical threshold, but notes this is an operational cutoff, not a physiological normal. Many academic centers and the Endocrine Society use 350 ng/dL as a threshold for consideration in symptomatic men. The most clinically meaningful evaluation asks not 'is this number above 264?' but rather: Is this number low for this individual's age? Is it consistent with their symptom burden? Is their free testosterone — the biologically active fraction — actually adequate? For the full list of symptoms that indicate low testosterone regardless of where the number falls, see low testosterone symptoms: 12 signs you have low T. For comprehensive lab panel guidance, see how to read testosterone lab results. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: being told by a provider that a testosterone level of 320 ng/dL is 'within normal limits' and requiring no follow-up, without any symptom assessment or free testosterone evaluation — this represents an incomplete clinical evaluation that misses a meaningful proportion of men with treatable hypogonadism. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Free testosterone and SHBG: why total testosterone alone can completely mislead you

Of all the testosterone your body has in circulation, only a fraction is biologically active. Roughly 98–99% of testosterone is bound to proteins — primarily sex hormone-binding globulin (SHBG) and, to a lesser extent, albumin. Testosterone bound to SHBG is essentially inactive — it cannot enter cells and activate androgen receptors. Only the unbound fraction (free testosterone, roughly 1–3% of total) and the albumin-bound fraction (loosely bound, bioavailable) actually drive the biological effects of testosterone. Buyers searching for testosterone levels by age chart usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

This matters profoundly for age-related interpretation because SHBG rises with age — often by 30–50% between ages 25 and 65 in healthy men, and much more in men with liver disease, hyperthyroidism, or chronic illness. A 58-year-old man with a total testosterone of 430 ng/dL and an SHBG of 55 nmol/L may have a free testosterone below 8 pg/mL — falling below the AUA threshold for clinically significant deficiency — despite a total T that appears borderline-adequate on the chart. The reverse is also true: a man with unusually low SHBG (from obesity, insulin resistance, hypothyroidism) may have a total testosterone of 260 ng/dL but a normal or near-normal free testosterone with no significant symptoms. The Bhasin 2019 guideline specifically recommends measuring free testosterone (calculated or direct assay) in men with symptoms of hypogonadism but borderline total T or elevated SHBG — exactly the situation most men over 45 find themselves in. Two methods exist: the calculated free T (using total T, SHBG, and albumin via the Vermeulen formula — preferred for accuracy) and the direct free T assay (equilibrium dialysis method, expensive but accurate; avoid the direct RIA method, which has poor accuracy). For the full technical guide on interpreting labs, see how to read testosterone lab results. For monitoring labs on TRT, see TRT monitoring guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: relying on total testosterone alone and being told 'you're fine' when elevated SHBG is producing functionally low free testosterone with significant symptoms — this is one of the most common missed diagnoses in men's hormone health. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

How testosterone actually declines with age — and what accelerates it

Understanding the biology of testosterone decline by age helps separate what is expected from what is preventable, and which declines warrant evaluation. The pattern is not 'cliff at 40' — it is a slow, variable downslope with significant individual differences driven by lifestyle, metabolic health, sleep quality, and whether secondary causes are present. Buyers searching for testosterone levels by age chart usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Testosterone production declines through two parallel mechanisms. Primary testicular aging: Leydig cell number and function decline gradually with age, producing less testosterone per unit of LH stimulus. This is the irreducible biological component — it happens in every man, cannot be reversed, but accounts for only part of the observed decline. Secondary HPG axis changes: The hypothalamus produces less GnRH pulsatility with age, and the pituitary reduces LH sensitivity in some men. This component is more variable and more sensitive to lifestyle. Several factors accelerate testosterone decline beyond baseline aging, and these are clinically important because they are often modifiable: excess adiposity (adipose tissue converts testosterone to estradiol via aromatase, and directly suppresses HPG axis function — losing 10–15% of body weight can raise testosterone by 100–200 ng/dL in obese men); sleep deprivation and sleep disorders (obstructive sleep apnea produces dramatic testosterone suppression — some studies showing 10–15% acute decline from a single night of reduced sleep, per Leproult and Van Cauter 2011 JAMA; see TRT and sleep); chronic stress and cortisol elevation (HPA axis activation suppresses GnRH and LH — see the mechanism in TRT and anxiety); metabolic syndrome and insulin resistance; alcohol use above moderate levels; opioid and glucocorticoid medications; and previous anabolic steroid use, which can produce prolonged or permanent HPG axis suppression. The key clinical implication: a man in his 40s with testosterone of 320 ng/dL who is obese, sleep-deprived, and highly stressed may see his levels normalize substantially with lifestyle optimization — and this should be explored before committing to exogenous TRT. For the natural optimization strategy, see how to increase testosterone naturally. For the comparison of natural vs. TRT approaches, see TRT vs natural testosterone boosting. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: treating the decline as purely inevitable aging when significant modifiable contributors are present. Many men treated with TRT in their 40s and 50s had treatable secondary causes (obesity, sleep apnea, alcohol) that were never adequately addressed before hormone therapy was started. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Symptom correlation: when your testosterone level should prompt action regardless of the number

The number on the chart is a starting point. Symptoms are the clinical signal that determines whether that number is actually low for you. Two men with identical testosterone levels can have completely different clinical pictures — one is symptomatic and impaired, the other is asymptomatic and functioning well. This is partly explained by androgen receptor sensitivity variation, free testosterone differences from SHBG, and other hormone interactions. The clinical standard is symptoms-plus-labs, not labs alone. Buyers searching for testosterone levels by age chart usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The AUA defines clinical hypogonadism as the presence of symptoms consistent with testosterone deficiency combined with consistently low testosterone levels on morning blood draws. The symptoms associated with testosterone deficiency — reduced libido, decreased spontaneous erections, fatigue and low energy, reduced muscle mass and strength, increased body fat, reduced motivation and drive, brain fog and poor concentration, depressed mood and irritability, reduced bone density, and testicular volume reduction — are meaningful clinical indicators even when the testosterone level falls in the 'normal' statistical range. This is because population-based reference ranges encompass men with and without symptoms across all health conditions — they are a population snapshot, not an individual threshold. A practical approach: if a man has 4 or more symptoms from the validated ADAM questionnaire (Androgen Deficiency in Aging Males) and a total testosterone below 400 ng/dL on two morning draws, an evaluation for hypogonadism is clinically reasonable regardless of whether 400 is 'within the lab normal range.' Conversely, a man with testosterone of 280 ng/dL who has zero symptoms — robust libido, excellent energy, good body composition, no cognitive complaints — may not require treatment. The goal is symptom resolution and function, not chasing a target number. For the full symptom guide, see low testosterone symptoms. For the evaluation of which treatment approach fits which profile, see primary vs secondary hypogonadism and enclomiphene vs TRT. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: pursuing testosterone therapy based on a low number alone without symptom correlation — and conversely, being told a borderline number doesn't matter without any symptom assessment. Both represent incomplete evaluation. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

The 300 ng/dL threshold — and why the real conversation starts at 400

The AUA guideline threshold of 300 ng/dL is widely cited as the cutoff for hypogonadism treatment. But most experienced clinicians recognize that symptomatic men can have meaningful testosterone deficiency at levels well above this number — particularly when SHBG is elevated, when the decline from individual peak is steep, or when symptoms are severe. Buyers searching for testosterone levels by age chart usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The 300 ng/dL threshold has a practical origin: it represents approximately the 2.5th percentile of morning testosterone in healthy young adult men — a statistical floor, not a physiological optimal. For many men, their individual 'optimal' testosterone (where they felt best in their late 20s and 30s) may have been 600–800 ng/dL. A drop to 320 ng/dL represents a 50–60% decline from their personal baseline — a magnitude that is clinically significant regardless of where 320 falls relative to a population reference range. This is why many clinicians in men's hormone health practice apply a symptom-guided, individualized approach rather than a strict cutoff: evaluating whether testosterone levels are low relative to age-expected ranges AND whether the decline correlates with symptom emergence. Men in the 300–500 ng/dL range with significant symptom burden are a gray zone that population statistics cannot resolve — only a detailed clinical assessment can. For the specific treatment comparison including when enclomiphene (a SERM that stimulates endogenous production) may be preferable to exogenous TRT for secondary hypogonadism: see enclomiphene vs TRT. For cost planning before any treatment decision: see how much does TRT cost. For the complete protocol picture: see TRT protocol complete guide. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: dismissing significant testosterone decline and clinical symptoms because the absolute number remains above 300 ng/dL — or, conversely, treating a low number without adequate symptom correlation and missing another primary diagnosis driving the complaint. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Testing correctly: morning draw timing, variability, and what invalidates a result

One of the most common reasons for inaccurate testosterone results — both falsely low and falsely high — is improper testing conditions. Testosterone has a strong circadian rhythm and can vary 20–30% across the day and between days. Understanding proper testing protocol ensures your results are actually interpretable. Buyers searching for testosterone levels by age chart usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Testosterone follows a diurnal pattern: levels peak between 6–10 AM and decline through the day, reaching their trough in the afternoon and evening. The AUA recommends morning blood draws for testosterone testing, and most labs and clinical guidelines define reference ranges based on morning samples. An afternoon testosterone draw in a healthy young man can look like hypogonadism. Conversely, a morning draw in the same man with sleep deprivation or acute illness may be suppressed below his true baseline. Conditions that suppress testosterone acutely and invalidate testing include: acute illness or hospitalization (severe acute illness can suppress T by 30–50%); recent acute alcohol intake; acute severe sleep deprivation; recent intense exercise (within 24–48 hours); significant caloric deficit or fasting; and opioid medication use. These conditions can produce a temporary low result that normalizes once the acute stressor resolves. The clinical standard is two morning draws on separate days — not same-day repeat draws — before making a treatment decision. Same-morning repeats capture the same transient variability; separate-day draws capture the true average. A man who has one morning low result should have it confirmed on a separate morning before any treatment decision is made. For the complete monitoring and lab guide including draw timing relative to injections: see TRT monitoring guide. For how to read the full panel beyond total T: see how to read testosterone lab results. For comparing online TRT providers including lab coverage: see compare TRT providers. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: making treatment decisions based on a single afternoon testosterone draw, a draw during acute illness, or a draw after significant recent alcohol — all of which can produce artifactually low results that do not reflect true baseline. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

Interpreting your testosterone level correctly requires age context, free testosterone, SHBG, symptoms, and proper testing conditions — not just one number compared against a population reference range. Use our provider comparison tool to find clinics that order complete diagnostic panels, assess symptom burden properly, and take a measured, evidence-based approach to treatment decisions.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What is a normal testosterone level by age?

Reference ranges vary by decade. Approximate median values from population studies: 20s (~600–700 ng/dL), 30s (~550–650 ng/dL), 40s (~500–600 ng/dL), 50s (~450–550 ng/dL), 60s (~380–480 ng/dL), 70s+ (~300–400 ng/dL). These are population medians, not individual targets — significant variation exists, and where a man falls relative to symptoms and free testosterone matters more than comparison against these averages.

What testosterone level is considered low?

The AUA defines biochemical hypogonadism as total testosterone below 300 ng/dL on two morning draws, in combination with symptoms of testosterone deficiency. The Endocrine Society uses 350 ng/dL as a threshold for consideration in symptomatic men. Many experienced clinicians evaluate men in the 300–500 range based on symptom burden, free testosterone, and individual decline from estimated baseline — the absolute cutoff is a guideline, not a bright line.

Why do testosterone levels decline with age?

Testosterone declines through two mechanisms: primary testicular aging (Leydig cell function reduces gradually) and secondary HPG axis changes (reduced GnRH pulsatility and LH sensitivity). The rate of decline is highly variable. Factors that accelerate decline beyond baseline aging include excess body fat (aromatase-driven conversion to estradiol), sleep deprivation and sleep apnea, chronic stress, alcohol use, opioid medications, metabolic syndrome, and prior anabolic steroid use. Many men experience significant secondary causes that are partially modifiable.

Is a testosterone level of 400 ng/dL low?

It depends. A 35-year-old at 400 ng/dL with significant symptoms (reduced libido, fatigue, brain fog, reduced muscle, increased body fat) and a prior history of levels in the 600–700 range represents a meaningful decline that warrants evaluation. A 65-year-old at 400 ng/dL with no symptoms and good quality of life may not require any intervention. The number must be interpreted in the context of age, symptoms, free testosterone, and individual baseline — not as an absolute standard.

What does it mean if my testosterone is 'normal' but I have low T symptoms?

Several explanations exist. First, your free testosterone may be low despite normal total T — elevated SHBG binds more testosterone, leaving less biologically active free T available. Second, your personal baseline may have been significantly higher, making a 'normal' level functionally low for you specifically. Third, another condition (thyroid, sleep apnea, depression, B12 deficiency) may be driving the symptoms rather than testosterone. A complete evaluation includes free T, SHBG, LH/FSH, thyroid, sleep assessment, and symptom scoring.

How does SHBG affect testosterone interpretation?

SHBG (sex hormone-binding globulin) binds testosterone tightly, rendering it biologically inactive. SHBG rises with age, liver health changes, and thyroid status. A man with total T of 450 ng/dL and SHBG of 60 nmol/L may have a free testosterone below 8 pg/mL — clinically significant deficiency by most guidelines — despite a total T that appears borderline-normal. Conversely, low SHBG (from obesity or insulin resistance) means a man with total T of 280 ng/dL may have adequate free T. SHBG must be measured to interpret testosterone accurately in men over 40.

What time of day should I test testosterone?

Blood draws for testosterone should be collected between 7 and 10 AM. Testosterone peaks in the early morning and declines through the day — afternoon levels can be 20–30% lower than morning levels in healthy men. All published reference ranges are calibrated against morning draws. An afternoon result cannot be reliably compared against standard ranges and may lead to false diagnoses of deficiency or false reassurance of adequacy.

Can testosterone levels fluctuate significantly day to day?

Yes. Testosterone can vary 20–30% between draws due to differences in sleep quality, stress, time of draw, illness, exercise, alcohol, and circadian rhythm variation. This is why clinical guidelines recommend two confirmatory morning draws on separate days before making a treatment decision. A single low result — especially in the context of recent illness, poor sleep, or afternoon timing — should be confirmed before any action is taken.

What is the lowest testosterone level before TRT is considered?

The AUA threshold is 300 ng/dL on two morning draws with consistent symptoms. But TRT consideration is not purely about reaching a specific floor — it is about symptoms plus confirmed deficiency plus understanding the cause. Men with levels of 250–300 ng/dL and significant symptoms are typically clear candidates for evaluation. Men in the 300–500 range with symptoms require free testosterone, SHBG, and LH/FSH assessment before a recommendation. Men with normal free T despite low-normal total T (due to low SHBG) may not be candidates for TRT at all.

Does testosterone decline at the same rate for all men?

No — the rate of decline is highly variable. Large population studies show that while average decline is roughly 1–2% per year from peak, many men maintain robust testosterone levels into their 60s while others experience significant decline in their late 30s. Lifestyle factors (body weight, sleep, alcohol, stress, exercise) account for a substantial portion of the between-individual variation. Primary testicular aging is the irreducible biological component, but secondary causes — which are often modifiable — explain much of the variability observed across same-age men.